Core Insights - The 2025 Sustainable Global Leaders Conference will be held from October 16 to 18 in Shanghai, focusing on sustainable development and industry upgrades [1] - Fosun Pharma's Chairman Chen Yuqing emphasized the significant advancements in China's innovative drug industry over the past decade, with R&D numbers increasing from 5% in 2014 to 30% in 2024, nearing the U.S. figure of 35% [3][5] - Fosun Pharma's innovative drug licensing transactions reached over $60 billion in the first half of 2025, surpassing the total for the entire year of 2024 [3] Group 1: Conference Overview - The conference is co-hosted by the World Green Design Organization and Sina Group, with support from the Shanghai Huangpu District Government [1] - Key discussions will include creating a sustainable development model in Shanghai and exploring new growth paradigms for the city's five centers [1] Group 2: Fosun Pharma's Innovations - Fosun Pharma invests approximately 5 billion RMB annually in R&D, accounting for nearly 17% of its total pharmaceutical revenue [3][5] - The company has launched 12 innovative drugs since 2019, with four new products and five indications introduced in the first half of this year [3][5] Group 3: Global Expansion and ESG Commitment - Fosun Pharma has transitioned from being an "agent" to an integrated "R&D-manufacturing-sales" model, exemplified by the establishment of the largest Asia-Pacific headquarters for the Da Vinci surgical robot [5][6] - The company has supplied over 420 million doses of artemisinin-based products globally, treating over 84 million severe malaria patients, primarily children under five [6] - Fosun Pharma holds an MSCI ESG rating of AA, leading the industry, and is the only Chinese pharmaceutical company listed in the 2025 Fortune China ESG Impact List [7]

Core Viewpoint - Fosun Pharma announced that Shenzhen Biopharmaceutical Industry Fund plans to participate in the A-round financing of its subsidiary, Fosun Kerry, with a total investment of 600 million yuan [1] Group 1: Financing Details - The Shenzhen Biopharmaceutical Industry Fund intends to invest a total of 600 million yuan to subscribe for no more than 524.437452 million yuan of new registered capital in Fosun Kerry [1] - A total of 14 participants, including current directors and core management of Fosun Kerry, plan to invest 3.525 million yuan to subscribe for 3.08107 million yuan of new registered capital [1] Group 2: Incentive Plans - To attract and retain key talents that significantly contribute to the growth of Fosun Kerry, the company’s board approved an equity incentive plan on October 17 [1] - The incentive plan includes granting up to 932.19893 million yuan of incentive rights at a price of 0.76 yuan per 1 yuan of registered capital, with the first batch corresponding to no more than 761.8487 million yuan [1]

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Fuhong Hanlin Biotechnology Co., Ltd., has received Orphan-drug Designation from the FDA for its investigational drug HLX43, a PD-L1 targeted antibody-drug conjugate for the treatment of thymic epithelial tumors (TETs) [1] Group 1 - The investigational drug HLX43 is specifically designed for the treatment of thymic epithelial tumors [1] - The FDA's Orphan-drug Designation is a significant milestone for the company, potentially facilitating the drug's development and commercialization [1]

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Fuhong Hanlin Biotechnology Co., Ltd., has received Orphan-drug Designation from the FDA for its investigational drug HLX43, aimed at treating thymic epithelial tumors (TETs) [1] Group 1: FDA Orphan-drug Designation - The Orphan-drug Designation for HLX43 will facilitate its research, registration, and commercialization in the U.S. by providing various policy supports [1] - Benefits include tax credits for clinical trial costs, exemption from new drug application fees, and a seven-year market exclusivity without patent influence [1] Group 2: Market Considerations - If other drugs with the same indication are approved before HLX43, the company must demonstrate HLX43's superior efficacy in clinical settings to maintain the market exclusivity benefits [1]

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Fuhong Hanlin Biotechnology Co., Ltd., has received Orphan-drug Designation from the FDA for its investigational drug HLX43, aimed at treating thymic epithelial tumors (TETs) [1] Group 1: FDA Orphan-drug Designation - The Orphan-drug Designation for HLX43 will facilitate its subsequent research, registration, and commercialization in the U.S. by providing certain policy supports [1] - Benefits of the designation include tax credits for clinical trial costs, exemption from new drug application fees, and seven years of market exclusivity unaffected by patent status [1] Group 2: Market Considerations - If other drugs with the same indication are approved before HLX43, the company must demonstrate HLX43's superior efficacy in clinical settings to maintain the market exclusivity benefits associated with the orphan drug status [1]

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Fuhong Hanlin Biotechnology Co., Ltd., has received Orphan-drug Designation from the FDA for its investigational drug HLX43, aimed at treating thymic epithelial tumors (TETs) [1] Group 1: Drug Development - HLX43 is a targeted PD-L1 antibody-drug conjugate (ADC) developed by Fuhong Hanlin, combining a novel DNA topoisomerase I inhibitor with a self-developed PD-L1 targeting antibody [1] - The drug is intended for the treatment of advanced/metastatic solid tumors [1]

Group 1 - Fosun Pharma announced that its subsidiary, Fosun Kerry, signed a capital increase agreement with Shenzhen Biomedical Industry Fund for a total investment of 600 million yuan, aimed at supporting the operational and business development of Fosun Kerry [1] - The investment will be made in phases, with the new registered capital not exceeding 524.44 million yuan [1] - A co-investment agreement was also signed with 14 participants, including current directors and core management, who will contribute a total of 3.525 million yuan to the new registered capital of 3.081 million yuan [1] Group 2 - The co-investors include several directors and senior management, which constitutes a related party transaction under the Shanghai Stock Exchange Listing Rules [2] - These related party investors plan to contribute a total of 1.246664 million yuan to the new registered capital of 1.089664 million yuan [2] - An incentive plan was approved to attract and retain key talents, allowing for the issuance of equity rights worth up to 93.22 million yuan, with the first batch not exceeding 76.18 million yuan [2] Group 3 - The first batch of incentive rights includes several directors and senior management, also constituting a related party transaction [3] - If all incentive rights are fully vested, these related party investors could indirectly hold 12.76 million yuan of registered capital through a total investment of 9.694159 million yuan [3]

Core Points - Fosun Pharma announced a capital increase agreement with Shenzhen Biomedical Industry Fund for its subsidiary Fosun Kerry, involving a total investment of 600 million yuan for A-round financing [1] - The funds raised will be used for the operation and business development of Fosun Kerry and/or its subsidiaries [1] - A co-investment agreement was signed with 14 participants, including current directors and core management, committing a total of 3.525 million yuan to increase Fosun Kerry's registered capital [1] - The pre-investment valuation for this co-investment aligns with the capital increase [1] Related Transactions - The co-investors include several directors and senior management, which constitutes a related party transaction under the Shanghai Stock Exchange Listing Rules [2] - These related party co-investors plan to contribute a total of 1.246664 million yuan to increase Fosun Kerry's registered capital [2] Incentive Plan - To attract and retain key talent, Fosun Kerry's board approved an incentive plan on October 17, 2025, allowing for the issuance of equity incentives valued at up to 93.219893 million yuan [3] - The first batch of incentives will grant up to 76.184870 million yuan in registered capital [3] - The equity incentives will be sourced from shares transferred to the incentive platform by Fosun Pharma's subsidiary [3] Related Party Incentives - The first batch of incentive recipients includes several directors and senior management, which also constitutes a related party transaction [4] - If all granted incentives are fully vested, these related party recipients could indirectly hold 12.755472 million yuan in registered capital through an investment of 9.694159 million yuan [4]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 控股子公司藥品獲美國FDA孤兒藥資格認定的提示性公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 中國，上海 2025 年1 0 月1 7 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生及潘東輝先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生 及楊玉成先生；以及本公司之職工董事 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《上海 復健股權投資基金管理有限公司擬投資涉及的復星凱瑞（上海）生物科技有限公司股東全部 權益價值項目資產評估報告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2025 年1 0 月1 7 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生及潘東輝先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen ...